华润双鹤：羟钴胺注射液获得药物临床试验批准通知书

Core Viewpoint - The company has received the clinical trial approval notice for Hydroxocobalamin Injection from the National Medical Products Administration, indicating progress in its drug development efforts [2] Group 1: Drug Development - Hydroxocobalamin Injection is intended for the treatment of metabolic disorders in children with methylmalonic acidemia, with or without homocystinuria [2] - The total research and development investment for this drug has reached RMB 13.0581 million (unaudited) as of the date of the announcement [2]